317819-68-4|Tezampanel hydrate|3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, monohydrate, (3S,4aR,6R,8aR)-|-范德生物科技公司

Tezampanel hydrate

NMR下载 COA and HPLC MSDS下载
names：
3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, monohydrate, (3S,4aR,6R,8aR)-
CAS号：
317819-68-4
MDL Number：
MF(分子式)： C13H23N5O3 MW(分子量)： 297.359
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, monohydrate, (3S,4aR,6R,8aR)-
英文别名	LY 293558; LY-293558; LY293558; NGX-424; NGX 424; NGX424; Tezampanel
CAS号	317819-68-4
Inchi	InChI=1S/C13H21N5O2.H2O/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12;/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18);1H2/t8-,9+,10-,11+;/m1./s1
InchiKey	LNDYQNTTYXLTNH-RTBBDAMFSA-N
分子式 Formula	C13H23N5O3
分子量 Molecular Weight	297.359
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Tezampanel hydrate(CAS:317819-68-4 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Tezampanel is used for the treatment of migraine, neuropathic pain.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Apland JP, Aroniadou-Anderjaska V, Figueiredo TH, De Araujo Furtado M, Braga MFM. Full Protection Against Soman-Induced Seizures and Brain Damage by LY293558 and Caramiphen Combination Treatment in Adult Rats. Neurotox Res. 2018 Oct;34(3):511-524. doi: 10.1007/s12640-018-9907-[1]Epub 2018 Apr 30. PubMed PMID: 29713995.

[2]Apland JP, Aroniadou-Anderjaska V, Figueiredo TH, Prager EM, Olsen CH, Braga MFM. Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats. Neurotox Res. 2017 Nov;32(4):694-706. doi: 10.1007/s12640-017-9789-7. Epub 2017 Aug 3. PubMed PMID: 28776308.

[3] Miller SL, Aroniadou-Anderjaska V, Figueiredo TH, Prager EM, Almeida-Suhett CP, Apland JP, Braga MF. A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists. Toxicol Appl Pharmacol. 2015 Apr 15;284(2):204-16. doi: 10.1016/j.taap.2015.02.008. Epub 2015 Feb 15. PubMed PMID: 25689173; PubMed Central PMCID: PMC4545593.

[4] Prager EM, Figueiredo TH, Long RP 2nd, Aroniadou-Anderjaska V, Apland JP, Braga MF. LY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety. Neuropharmacology. 2015 Feb;89:11-8. doi: 10.1016/j.neuropharm.2014.08.014. Epub 2014 Sep 6. PubMed PMID: 25204221; PubMed Central PMCID: PMC4250288.

[5] Chan K, MaassenVanDenBrink A. Glutamate receptor antagonists in the management of migraine. Drugs. 2014 Jul;74(11):1165-76. doi: 10.1007/s40265-014-0262-0. Review. PubMed PMID: 25030431.

6: Moshiri M, Darchini-Maragheh E, Balali-Mood M. Advances in toxicology and medical treatment of chemical warfare nerve agents. Daru. 2012 Nov 28;20(1):81. doi: 10.1186/2008-2231-20-81. PubMed PMID: 23351280; PubMed Central PMCID: PMC3556041.7: Wallace MS, Lam V, Schettler J. NGX426, an oral AMPA-kainate antagonist, is effective in human capsaicin-induced pain and hyperalgesia. Pain Med. 2012 Dec;13(12):1601-10. doi: 10.1111/j.1526-4637.2012.01509.x. Epub 2012 Oct 30. PubMed PMID: 23110368.8: Apland JP, Aroniadou-Anderjaska V, Figueiredo TH, Green CE, Swezey R, Yang C, Qashu F, Braga MF. Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration. J Pharmacol Exp Ther. 2013 Jan;344(1):133-40. doi: 10.1124/jpet.112.198689. Epub 2012 Oct 5. PubMed PMID: 23042954; PubMed Central PMCID: PMC3533413.9: Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, Simmaco M, Smith T, Al-Kaisy A, Arcioni R, Martelletti P. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012 Sep;17(3):393-406. doi: 10.1517/14728214.2012.709846. Epub 2012 Aug 3. Review. PubMed PMID: 22862686.10: Moon MJ, Kim HY, Park S, Kim DK, Cho EB, Hwang JI, Seong JY. Insulin contributes to fine-tuning of the pancreatic beta-cell response to glucagon-like peptide-1. Mol Cells. 2011 Oct;32(4):389-95. doi: 10.1007/s10059-011-0157-9. Epub 2011 Sep 7. PubMed PMID: 21904878; PubMed Central PMCID: PMC3887647.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开